Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors

Total Page:16

File Type:pdf, Size:1020Kb

Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population. Method This study is a retrospective analysis of the Korean National Health Insurance Service (KNHIS) National Sample Cohort (NSC) 2002-2013. Adult patients who were initiated with ACEI or ARB in 2004-2012 were selected. The ACEI group and the ARB group were matched by the propensity score. The covariates that can affect the likelihood of antitussive treatment were identified using the Andersen’s behavioral model of health services utilization. A multivariate logistic regression was used to assess the likelihood of antitussive use after the initiation of ACEI and the likelihood of hospital switching. The difference in duration of ACEI therapy was tested using a t-test. The difference in ACEI therapy adherence, which was measured by prescription days covered, were tested using the chi-squared test. Results A total 19,793 patients who were initiated with ACEI in 2004-2012 were matched with 39,586 patients who were initiated with ARB in in the same period. The initiation of ACEI was significantly associated with the likelihood of antitussive treatment (OR 2.241; 95% CI 2.142-2.345). In terms of the type of hospitals where the ACEI was initiated, the likelihood of the hospital switch is significantly lower for primary than tertiary hospitals (OR 0.069; 95% CI 0.057-0.083). However in terms of hype of hospitals where the antitussives were first prescribed after the ACEI initiation, the primary hospitals were significantly more associated with the hospital switching than tertiary hospitals (OR 26.806; 95% CI 21.173-33.937) The patients who were treated with antitussives after the ACEI initiation were on ACEI therapy longer than those who did not use antitussives (mean ± SD 117.9 ± 80.4 days vs. 112.0 ± 84.6 days; p < 0.001). The long-term ACEI therapy adherence was lower in patients with antitussive use than those without antitussive use (46.1% vs. 49.5%, p = 0.012). Conclusion This study found that the cough patients who were initiated with ACEI are often treated symptomatically with antitussives in Korea, instead of discontinuing ACEI. The antitussive treatment decreased the ACEI therapy adherence. A preventive approach from inappropriate prescription of antitussives secondary to ACEI-induced cough would be necessary. Key words : Angiotensin-Converting Enzyme Inhibitor, Cough, Antitussive Student number : 2015-23175 Table of Contents I. Introduction ··································································································· 4 II. Literature Review ························································································ 6 1. ACEI-induced Cough ············································································ 6 2. Korean National Health Insurance Service National Sample Cohort ········································································································ 7 III. Method ·········································································································· 10 1. Study Design and Subjects ····························································· 10 2. Measurements ······················································································· 13 3. Statistical Analysis ·············································································· 17 IV. Result ············································································································ 19 1. Antitussive Treatment after ACEI or ARB initiation ·············· 19 2. Hospital Switching ··············································································· 23 3. The effect of the antitussive use on ACEI therapy ·············· 28 V. Discussion ···································································································· 29 VI. Conclusion ··································································································· 34 VII. Reference ····································································································· 35 VIII. 국문 초록 ······································································································· 39 - 1 - Table of Contents (Tables) Table 1. Composition of the Korean National Health Insurance Service National Sample Cohort ·········································· 9 Table 2. ATC Codes and Generic Names of ACEI and ARB ····· 11 Table 3. ATC Codes and Generic Names of Antitussives ·········· 14 Table 4. Diagnostic categories of Charlson Comorbidity Index and Corresponding ICD-10 Codes ····································· 16 Table 5. Characteristics of the ACEI and ARB initiators ··········· 19 Table 6. Multivariate Logistic Regression Model for Antitussive Use after ACEI/ARB Initiation ············································· 22 Table 7. Characteristics of the patients who switched and did not switch hospitals ································································ 24 Table 8. Multivariate Logistic Regression Model for Hospital Switching ····················································································· 26 Table 8. ACEI Therapy Duration and Adherence ·························· 28 - 2 - Table of Contents (Figures) Figure 1. Structure of the National Health Insurance Program in Korea ······················································································· 8 Figure 2. Structure of the Korean National Health Insurance Service National Sample Cohort ········································· 9 Figure 3. Screening, Inclusion, and Follow up Periods ·············· 10 Figure 4. Flowchart of the Study Subject Selection Process ··· 12 Figure 5. Andersen’s Behavioral Model and Utilized Variables ···················································································· 13 - 3 - I. Introduction Angiotensin-Converting Enzyme Inhibitor (ACEI) is used as a primary drug in many chronic diseases, especially in hypertension, heart failure, and chronic kidney disease, by inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) (Brugts et al., 2009). The incidence of ACEI-induced adverse drug reactions was reported to be lower than that of other cardiovascular drugs, but the most common side effect of ACEI is a dry cough, which is known to be the major cause of poor tolerability (Israili & Hall, 1992). The incidence of ACEI-induced cough is about 5-20% among Western populations, but is two times higher among Asians (Woo KS & Nicholls, 1995; Na et al., 2000; Ng & Goh, 2014). It was reported that ACEI-induced cough usually occurs within 4 weeks after the drug initiation although it may be delayed up to 6 months (Israili et al., 1992). The symptom resolves within several weeks after the discontinuation of the drug (Israili et al., 1992). Therefore, instead of using antitussives for the cough, most medical guidelines that were revised in the early 2000s, including the JNC-7 hypertension guidelines, 2005 ACCF/AHA heart failure guidelines, and 2004 KDOQI chronic kidney disease guidelines recommended to switch to Angiotensin II Receptor Blocker (ARB) which has similar mechanism of action with a much lower rate of cough compared to ACEI (Chobanian et al., 2003; Hunt et al., 2005; Kidney Disease Outcomes Quality Initiative, 2004). In Korea, a previous study reported that the incidence of ACEI-induced cough in Koreans is 40.1% with a significant risk factor of female gender (Na et al., 2000). Since the primary care physician system is not present in Korea, patients in Korea often switch their physician (Shin et al., 2011); for example, if a patient - 4 - with newly prescribed ACEI visits a physician other than the original ACEI prescriber such as otolaryngologist due to a cough, the physician will find it difficult to determine whether the patient is suffering from a simple acute upper respiratory infection such as a common cold or a side effect caused by ACEI. Therefore it is expected that the rate of cough misdiagnosis and inappropriate antitussive prescription
Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Dose Finding Studies with Imidapril-A New ACE Inhibitor
    Br J clin Pharmac 1994; 37: 265-272 Dose finding studies with imidapril-a new ACE inhibitor M. J. VANDENBURG', E. M. MACKAY1, I. DEWS1, T. PULLAN1 & S. BRUGIER2 1MCRC, Lewis House, 1 Mildmay Road, Romford, Essex, UK and 2Tanabe Pharma, 12 Avenue d'Italie, 75013 Paris, France 1 We describe an approach involving a smaller, shorter study, leading onto a longer, larger study in which the antihypertensive effects of ascending doses of imidapril, a new ACE inhibitor, were investigated. Both studies were planned prospectively, assuming a clinically useful fall in BP to be 8 mm Hg (s.d. = 9). The studies included patients with mild to moderate essential hypertension (baseline sitting diastolic blood pressure (SDBP) 95-115 mm Hg). After a placebo run-in of 2-3 weeks patients received either placebo or imidapril 2.5, 5, 10 or 20 mg in the 2 week study (n = 91) or imidapril 5, 10, 20 or 40 mg in the 4 week study (n = 162). 2 The overall mean baseline SDBP was 103.4 mm Hg (s.d. 0.62) in the initial study and 101.5 mm Hg (s.d. 0.41) in the 4 week study. 3 Compared with placebo, imidapril 10, 20 and 40 mg significantly reduced SDBP. There was no significant difference between these doses, suggesting that 10 mg achieved maximal ACE inhibition in most patients. The 2.5 mg dose showed no significant effect. The 5 mg dose gave an intermediate effect. In both studies the overall incidence of adverse events was similar in the imidapril and placebo groups, and was not worrying.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Fimasartan Clinical Trial: Direction for Acute Myocardial Infarction
    Myung Ho Jeong, MD, PhD, FACC, FAHA, FESC, FSCAI, FAPSIC Professor, Principal Investigator of Korea Acute Myocardial Infarction Registry, Director of Heart Research Center Designated by Korea Ministry of Health and Welfare, Director of Korea Cardiovascular Stent Research Institute, Chonnam National University Hospital, Gwangju, Korea Losartan Valsartan Irbesartan N M3C N M3C CH3 HN HN N N HN N HO N N N N N N N CH O 3 O N O HO O N CH3 Candesartan Olmesartan Telmisartan O N O HN N O HO N O CH3 HO O N O O HN N N CH3 N N N N HO CH O M C N 3 N 3 N CH3 CH3 CH3 CH3 Ries et al. J Med Chem 1993;36:4040–4051 2 c a b Brand Name: KANARB (KHAN of ARBs) Active Pharmaceutical Ingredient: Fimasartan potassium trihydrate, C27H30N7OS·K·3H2O Molecular Weight = 593.79 pH = 6~8 (water, 50mg/10mL) T1/2(hr) : 7-10 Solubility: freely soluble in MeOH, soluble in EtOH, slightly soluble in water 3 AT1 receptor Fimasartan By Discovery Studio 2.5, Accelys Inc., CA, USA 4 Losartan Valsartan Irbesartan Eprosartan Telmisartan Olmesartan Candesartan Fimasartan Tmax (hr) 3-4 2-4 1.5-2 1-2 0.5-1 1-2 3-4 0.5~3 2 T1/2 (hr) (EXP3174: 6-9 11-15 5-9 24 13 5-9 7-10 6-9) Active EXP3174 None None None None None None None metabolite Protein 99 95 90-92 98 99.5 99 >99 >97 Binding (%) Bioavailability 33 10-35 60-80 13 42-58 26 15 30-40 (%) Urinary 35 13 20 7 <1 35-50 33-59 <3 Elimination (%) Dose*1 (mg) 25, 50, 100 40,80,60,320 75, 150,300 400, 600 20, 40, 80 5, (10*2), 20, 40 4, 8, 16, 32 60, 120 AT1 binding Competitive Competitive Competitive Competitive Non-competitive Non-competitive
    [Show full text]
  • Influence of Erdosteine, a Mucolytic Agent, on Amoxycillin Penetration Into Sputum in Patients with an Infective Exacerbation of Chronic Bronchitis
    Thorax: first published as 10.1136/thx.43.8.585 on 1 August 1988. Downloaded from Thorax 1988;43:585-590 Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis GIOVANNI RICEVUTI, ANTONINO MAZZONE, ELVIRA UCCELLI, GABRIELLA GAZZANI, GIANCARLO B FREGNAN From the Section ofMedical Pathology I, Department ofInternal Medicine and Therapeutics, University of Pavia; the Department ofPharmaceutical Chemistry, University ofPavia; and the Research Center Laboratories, Ednond Pharma SRL, Milan, Italy ABSTRACT Twenty four patients with acute infective exacerbations of chronic bronchitis received amoxycillin alone or in combination with erdosteine (a mucolytic agent) for a week in a double blind, placebo controlled study. Clinical assessment scores, body temperature, serum and sputum amoxycillin concentrations, and sputum culture results were recorded in each group. Erdosteine significantly increased antibiotic concentrations in sputum but not in serum. The combined treatment also caused a more rapid decrease in sputum viscosity and in body temperature and faster sterilisation of the sputum. These results show that erdosteine increases amoxycillin concentration in sputum in patients with acute exacerbations ofchronic bronchitis. This effect may be due to a reduction in the viscosity of the bronchial secretions produced by erdosteine. copyright. Introduction Methods Although the exact role ofbacterial infections in acute PATIENTS exacerbations of chronic bronchitis is not clear, Twenty four patients (10 male and 14 female, aged 45- antibiotic treatment is widely used. In some patients, 71 years) with chronic bronchitis were studied during http://thorax.bmj.com/ however, the high viscosity ofthe bronchial secretions an acute, severe infective exacerbation.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]